FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lew Jennifer						ADURO BIOTECH, INC. [ADRO]									tionship of Reporting all applicable) Director Officer (give title		10% Ov Other (s		vner	
	(F URO BIOT NZ AVENU	- ,		3. Date of Earliest Transaction (Month/Day/Year) 12/01/2017								X	below) below) Sr. Vice President of Finance							
(Street) BERKEI (City)			94710 (Zip)		_ 4. It	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indiv ine) X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - N	on-Deriv	/ative	e Sec	uriti	ies Ac	quire	d, Di	sposed o	of, or Be	enefici	ally (Owned	ł				
Date				2. Transac Date (Month/Da		Exec) if an	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			and 5) Securiti Benefic Owned		es ially Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	Common Stock 12/01/2			2017)17			M		6,600	A	\$0.8	32	68	,938		D			
Common	Stock			12/01/2	2017				S ⁽¹⁾		6,600	D	\$9.45	95 ⁽²⁾	²⁾ 62,338 D					
		1	able II								posed of converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med on Date, Day/Year)	4. Transa Code (8)				6. Date Exerci Expiration Da (Month/Day/Y		ite	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (In	B. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amour or Number of Shares	er						
Stock Option (Right to	\$0.82	12/01/2017			M			6,600	(3)		11/26/2023	Common Stock	6,600		\$0.00	50,709		D		

Explanation of Responses:

- 1. The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.25 to \$9.525, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The shares subject to the Option are fully vested and immediately exercisable.

Remarks:

/s/ Jennifer Lew

12/04/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.